0	14	Autoregulation	autoregulation	NN
15	17	of	of	IN
18	21	the	the	DT
22	30	NF-kappa	NF-kappa	NNP
31	32	B	B	NNP
33	47	transactivator	transactivator	NN
48	52	RelA	RelA	NNP
53	54	(	(	(
54	57	p65	p65	NN
57	58	)	)	)
59	61	by	by	IN
62	70	multiple	multiple	JJ
71	82	cytoplasmic	cytoplasmic	JJ
83	93	inhibitors	inhibitor	NNS
94	104	containing	contain	VBG
105	112	ankyrin	ankyrin	NN
113	119	motifs	motif	NNS
119	120	.	.	.

122	126	RelA	RelA	NNP
127	128	(	(	(
128	131	p65	p65	NN
131	132	)	)	)
133	142	functions	function	VBZ
143	145	as	as	IN
146	149	the	the	DT
150	158	critical	critical	JJ
159	174	transactivating	transactivate	VBG
175	184	component	component	NN
185	187	of	of	IN
188	191	the	the	DT
192	205	heterodimeric	heterodimeric	JJ
206	213	p50-p65	p50-p65	NN
214	222	NF-kappa	NF-kappa	NNP
223	224	B	B	NNP
225	232	complex	complex	NN
233	236	and	and	CC
237	245	contains	contain	VBZ
246	247	a	a	DT
248	261	high-affinity	high-affinity	JJ
262	269	binding	bind	VBG
270	274	site	site	NN
275	278	for	for	IN
279	282	its	its	PRP$
283	294	cytoplasmic	cytoplasmic	JJ
295	304	inhibitor	inhibitor	NN
304	305	,	,	,
306	307	I	i	NN
308	313	kappa	kappa	NN
314	315	B	B	NNP
316	321	alpha	alpha	NN
321	322	.	.	.

323	328	After	after	IN
329	337	cellular	cellular	JJ
338	348	activation	activation	NN
348	349	,	,	,
350	351	I	i	NN
352	357	kappa	kappa	NN
358	359	B	B	NNP
360	365	alpha	alpha	NN
366	368	is	be	VBZ
369	376	rapidly	rapidly	RB
377	385	degraded	degrade	VBN
386	388	in	in	IN
389	396	concert	concert	NN
397	401	with	with	IN
402	405	the	the	DT
406	413	induced	induce	VBN
414	421	nuclear	nuclear	JJ
422	435	translocation	translocation	NN
436	438	of	of	IN
439	447	NF-kappa	NF-kappa	NNP
448	450	B.	B.	NNP
451	454	The	the	DT
455	462	present	present	JJ
463	468	study	study	NN
469	481	demonstrates	demonstrate	VBZ
482	486	that	that	IN
487	492	tumor	tumor	NN
493	501	necrosis	necrosis	NN
502	508	factor	factor	NN
509	522	alpha-induced	alpha-induced	JJ
523	534	degradation	degradation	NN
535	537	of	of	IN
538	539	I	i	NN
540	545	kappa	kappa	NN
546	547	B	B	NNP
548	553	alpha	alpha	NN
554	556	in	in	IN
557	562	human	human	JJ
563	564	T	t	NN
565	570	cells	cell	NNS
571	573	is	be	VBZ
574	582	preceded	precede	VBN
583	585	by	by	IN
586	589	its	its	PRP$
590	595	rapid	rapid	JJ
596	611	phosphorylation	phosphorylation	NN
612	614	in	in	FW
615	619	vivo	vivo	FW
619	620	.	.	.

621	628	However	however	RB
628	629	,	,	,
630	635	these	these	DT
636	643	effects	effect	NNS
644	646	on	on	IN
647	648	I	i	NN
649	654	kappa	kappa	NN
655	656	B	B	NNP
657	662	alpha	alpha	NN
663	669	result	result	VBP
670	672	in	in	IN
673	680	nuclear	nuclear	JJ
681	693	mobilization	mobilization	NN
694	696	of	of	IN
697	701	only	only	RB
702	703	a	a	DT
704	712	fraction	fraction	NN
713	715	of	of	IN
716	719	the	the	DT
720	726	entire	entire	JJ
727	738	cytoplasmic	cytoplasmic	JJ
739	743	pool	pool	NN
744	746	of	of	IN
747	751	RelA	RelA	NNP
751	752	.	.	.

753	763	Subsequent	subsequent	JJ
764	771	studies	study	NNS
772	776	have	have	VBP
777	785	revealed	reveal	VBN
786	790	that	that	IN
791	792	(	(	(
792	793	i	i	LS
793	794	)	)	)
795	806	cytoplasmic	cytoplasmic	JJ
807	811	RelA	rela	NN
812	814	is	be	VBZ
815	821	stably	stably	RB
822	832	associated	associate	VBN
833	836	not	not	RB
837	841	only	only	RB
842	846	with	with	IN
847	848	I	i	NN
849	854	kappa	kappa	NN
855	856	B	B	NNP
857	862	alpha	alpha	NN
863	866	but	but	CC
867	871	also	also	RB
872	876	with	with	IN
877	882	other	other	JJ
883	890	ankyrin	ankyrin	NN
891	901	motif-rich	motif-rich	JJ
902	910	proteins	protein	NNS
911	920	including	include	VBG
921	924	the	the	DT
925	933	products	product	NNS
934	936	of	of	IN
937	940	the	the	DT
941	949	NF-kappa	NF-kappa	NNP
950	952	B2	b2	NN
953	954	(	(	(
954	958	p100	p100	NN
958	959	)	)	)
960	963	and	and	CC
964	972	NF-kappa	NF-kappa	NNP
973	975	B1	B1	NNP
976	977	(	(	(
977	981	p105	p105	NN
981	982	)	)	)
983	988	genes	gene	NNS
988	989	;	;	:
990	991	(	(	(
991	993	ii	ii	LS
993	994	)	)	)
995	997	in	in	IN
998	1006	contrast	contrast	NN
1007	1009	to	to	TO
1010	1016	RelA-I	RelA-I	NNP
1017	1022	kappa	kappa	NN
1023	1024	B	B	NNP
1025	1030	alpha	alpha	NN
1030	1031	,	,	,
1032	1041	RelA-p100	RelA-p100	NNP
1042	1053	cytoplasmic	cytoplasmic	JJ
1054	1063	complexes	complex	NNS
1064	1067	are	be	VBP
1068	1071	not	not	RB
1072	1083	dissociated	dissociate	VBN
1084	1093	following	follow	VBG
1094	1099	tumor	tumor	NN
1100	1108	necrosis	necrosis	NN
1109	1115	factor	factor	NN
1116	1121	alpha	alpha	NN
1122	1132	activation	activation	NN
1132	1133	;	;	:
1134	1135	(	(	(
1135	1138	iii	iii	LS
1138	1139	)	)	)
1140	1144	p100	p100	NN
1145	1154	functions	function	VBZ
1155	1157	as	as	IN
1158	1159	a	a	DT
1160	1166	potent	potent	JJ
1167	1176	inhibitor	inhibitor	NN
1177	1179	of	of	IN
1180	1193	RelA-mediated	rela-mediated	JJ
1194	1207	transcription	transcription	NN
1208	1210	in	in	FW
1211	1215	vivo	vivo	FW
1215	1216	;	;	:
1217	1218	(	(	(
1218	1220	iv	iv	LS
1220	1221	)	)	)
1222	1225	the	the	DT
1226	1237	interaction	interaction	NN
1238	1240	of	of	IN
1241	1245	RelA	RelA	NNP
1246	1249	and	and	CC
1250	1254	p100	p100	NN
1255	1263	involves	involve	VBZ
1264	1267	the	the	DT
1268	1277	conserved	conserve	VBN
1278	1281	Rel	Rel	NNP
1282	1290	homology	homology	NN
1291	1297	domain	domain	NN
1298	1300	of	of	IN
1301	1305	both	both	DT
1306	1314	proteins	protein	NNS
1315	1318	but	but	CC
1319	1322	not	not	RB
1323	1326	the	the	DT
1327	1334	nuclear	nuclear	JJ
1335	1347	localization	localization	NN
1348	1354	signal	signal	NN
1355	1357	of	of	IN
1358	1362	RelA	RelA	NNP
1362	1363	,	,	,
1364	1369	which	which	WDT
1370	1372	is	be	VBZ
1373	1381	required	require	VBN
1382	1385	for	for	IN
1386	1387	I	i	NN
1388	1393	kappa	kappa	NN
1394	1395	B	B	NNP
1396	1401	alpha	alpha	NN
1402	1409	binding	binding	NN
1409	1410	;	;	:
1411	1412	(	(	(
1412	1413	v	v	LS
1413	1414	)	)	)
1415	1419	p100	p100	NN
1420	1430	inhibition	inhibition	NN
1431	1433	of	of	IN
1434	1438	RelA	RelA	NNP
1439	1447	function	function	NN
1448	1456	requires	require	VBZ
1457	1460	the	the	DT
1461	1471	C-terminal	c-terminal	JJ
1472	1479	ankyrin	ankyrin	NN
1480	1485	motif	motif	NN
1486	1492	domain	domain	NN
1492	1493	,	,	,
1494	1499	which	which	WDT
1500	1508	mediates	mediate	VBZ
1509	1520	cytoplasmic	cytoplasmic	JJ
1521	1530	retention	retention	NN
1531	1533	of	of	IN
1534	1538	RelA	RelA	NNP
1538	1539	;	;	:
1540	1543	and	and	CC
1544	1545	(	(	(
1545	1547	vi	vi	LS
1547	1548	)	)	)
1549	1551	as	as	IN
1552	1560	observed	observe	VBN
1561	1565	with	with	IN
1566	1567	I	i	NN
1568	1573	kappa	kappa	NN
1574	1575	B	B	NNP
1576	1581	alpha	alpha	NN
1581	1582	,	,	,
1583	1590	nuclear	nuclear	JJ
1591	1595	RelA	RelA	NNP
1596	1606	stimulates	stimulate	VBZ
1607	1611	p100	p100	NN
1612	1616	mRNA	mrna	NN
1617	1620	and	and	CC
1621	1628	protein	protein	NN
1629	1639	expression	expression	NN
1639	1640	.	.	.

1641	1646	These	these	DT
1647	1655	findings	finding	NNS
1656	1660	thus	thus	RB
1661	1667	reveal	reveal	VBP
1668	1671	the	the	DT
1672	1680	presence	presence	NN
1681	1683	of	of	IN
1684	1685	a	a	DT
1686	1692	second	second	JJ
1693	1702	inducible	inducible	JJ
1703	1716	autoregulated	autoregulated	JJ
1717	1727	inhibitory	inhibitory	JJ
1728	1735	pathway	pathway	NN
1736	1740	that	that	WDT
1741	1746	helps	help	VBZ
1747	1753	ensure	ensure	VB
1754	1757	the	the	DT
1758	1763	rapid	rapid	JJ
1764	1767	but	but	CC
1768	1777	transient	transient	JJ
1778	1784	action	action	NN
1785	1787	of	of	IN
1788	1795	nuclear	nuclear	JJ
1796	1804	NF-kappa	NF-kappa	NNP
1805	1806	B	B	NNP
1806	1807	.	.	.